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he Pre-Clinical Animal Model in the Translational
esearch of Interventional Cardiology
oriyasu Suzuki, MD,*† Alan C. Yeung, MD,* Fumiaki Ikeno, MD*
tanford, California; and Aichi, Japan
cientiﬁc discoveries for improvement of human health must be translated into practical applications.
uch discoveries typically begin at “the bench” with basic research, then progress to the clinical level.
n particular, in the ﬁeld of interventional cardiology, percutaneous cardiovascular intervention has rap-
dly evolved from an experimental procedure to a therapeutic clinical setting. Pre-clinical studies using
nimal models play a very important role in the evaluation of efﬁcacy and safety of new medical de-
ices before their use in human clinical studies. This review provides an overview of the emerging role,
esults of pre-clinical studies and development, and evaluation of animal models for percutaneous car-
iovascular intervention technologies for patients with symptomatic cardiovascular disease. (J Am
oll Cardiol Intv 2009;2:373–83) © 2009 by the American College of Cardiology Foundationb
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phe invasive/noninvasive therapies of cardiovascu-
ar disease have advanced dramatically over the last
decades. Such advances typically begin with basic
esearch, then progress to the clinical level. Scien-
ists are increasingly aware that this bench-to-
edside approach to translational research is really
2-way street. Basic scientists provide clinicians
ith new tools for use in patients and for assess-
ent of their impact, and clinical researchers make
ovel observations about the nature and progres-
ion of disease that often stimulate basic investiga-
ions. In particular, in the field of interventional
ardiology, percutaneous cardiovascular interven-
ion has evolved from a quirky experimental pro-
edure to a therapeutic cornerstone for patients
ith symptomatic cardiovascular disease. In the
evelopment of these technologies, the role of
re-clinical testing using animal models, especially
arge animal models such as porcine, rabbit, and
vine, is a very important part of the regulatory
rocess that is used to determine the safety of
evices before human clinical trials. Once these
echnologies enter the clinical arena (bench to
rom the *Division of Cardiovascular Medicine, School of Medicine,
tanford University, Stanford, California; and the †Department of
ardiovascular Medicine, Nagoya Heart Center, Aichi, Japan.m
anuscript received August 18, 2008; revised manuscript received
ebruary 19, 2009, accepted March 8, 2009.edside), a further understanding of their thera-
eutic mechanisms can be realized through com-
arative analysis of animal model research findings
ith those of clinical pathological specimens (bed-
ide to bench).
This review will provide an overview of the
linical application status and limitations of current
ercutaneous cardiovascular intervention technol-
gies, and results of pre-clinical studies including
nimal models.
xperimental Animal Model for
oronary Intervention
rug-eluting stents (DES) have driven a new era
n the field of percutaneous coronary intervention
1,2). The first-generation DES coated with anti-
roliferative drugs have been shown to limit in-
tent restenosis in discrete lesions (3,4). The suc-
ess of these DES technologies is founded not only
n initial human clinical data but also on pre-
linical studies using the porcine coronary resteno-
is model (5–8). Presently, it is unclear whether
ny single animal species is more predictive of the
uman response to such coated stents. As such, we
aintain that animal models can still provide
echanistic insight into fundamental biological
rocesses and response. Therefore, these animal
odels can help prove critical hypotheses regard-
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374ng putative mechanisms of action of an intervention, yet
hey cannot be used to predict efficacy (9).
The rabbit iliac restenosis model has been studied exten-
ively to test restenosis therapies and to understand cellular
nd molecular mechanisms (10–12). Although balloon
ngioplasty in this model does cause histopathologic injury
omparable to that seen with human angioplasty, a criticism
f this model is that foam cells are rare in human restenotic
eointima.
The coronary arteries of domestic pigs after injury re-
pond in a similar fashion as human coronary arteries, and
hick neointima will be seen within 28 days and is identical
o human restenotic neointima (Fig. 1) (13,14). In addition,
he amount of neointimal thickening is directly proportional
o injury, thereby permitting the creation of an injury-
esponse regression relationship that can further quantify
he response to potential treatment therapies (15,16).
Experience suggests that the
coronary arteries in domestic
swine and iliac arteries of rabbits
are suitable for assessment of
devices that might be used in
clinical evaluation (17).
Porcine coronary restenosis model
for evaluation of DES technol-
ogies. Pre-clinical evaluation of
novel DES technologies has
great importance for under-
standing safety and possibly ef-
ficacy of these technologies, and
the porcine coronary restenosis
model is widely used for those
studies. In general, cardiac cath-
eterization techniques in the pig
are similar to the techniques
used in humans (18–21) (Fig. 1).
A pre-clinical studies consensus
roup (9,22) recommends that the stent be appropriately
ized by visual or quantitative coronary artery measurement
sing a stent/artery ratio1:1, as using a higher stent/artery
atio could induce severe arterial injury and considerable
oronary artery stenosis. There is no doubt that the arteries
n animals cannot be fully representative of human disease,
hus the pre-clinical studies can prove only safety and not
rue efficacy. However, pre-clinical animal studies still have
redictive value because biological processes associated with
rterial repair are similar. For standardization purposes, all
aboratories should use similar criteria for evaluation of
istopathologic change after stent implantation as follows.
NJURY AND INFLAMMATION SCORE. Inflammation by his-
opathologic evaluation can include an injury score at each
tent strut site. Inflammation descriptions have been pub-
bbreviations
nd Acronyms
S  aortic stenosis
TO  chronic total
cclusion
ES  drug-eluting stent(s)
AA  left arterial
ppendage
I  myocardial infarction
R  mitral regurgitation
ES  paclitaxel-eluting
tent(s)
FO  patent foramen ovale
ES  sirolimus-eluting
tent(s)
HD  valvular heart
iseaseished previously (14,23). iTENT STRUT POSITION AND ADJACENT TISSUE. Other ob-
ervational data should include stent strut apposition to the
essel wall, stent struts covered by tissue or endothelium,
djacent tissue, including medial thinning, loss of cellularity,
nd hyalinization.
TENT DESIGNS. Taylor et al. (24) have studied 4 different
tent designs to compare their effects on arterial injury,
ellular proliferation, neointima formation, and arterial
imensions. In that study, all 4 stent designs had similar
njury scores, cellular proliferation indices, and adventitial
reas. Nitinol stents resulted in a 2-fold increase in neoin-
imal area and thickness despite the lumen area being
imilar for all stent designs because of an offsetting expan-
ion in vessel area in nitinol stents (20% greater than
alloon-expandable stents) occurring between 7 and 14 days
fter stent deployment.
ASCULAR RESPONSE AND HEALING. Drug choice and re-
ease kinetics are the most important components of DES
echnology because they determine the type of vascular
esponse and time course of healing (25–28). Endothe-
ialization after stent implantation should be recorded as
bsent, partial, or complete in all sections and the time of
e-endothelialization should be estimated. In the porcine
oronary stent model, a thick neointima was reliably
Figure 1. Porcine and Human Epicardial Coronary Anatomy
Porcine: (A) right coronary artery and (B) left coronary system. Human: (C)
right coronary artery and (D) left coronary system. Similar anatomy and
coronary distribution is shown of the left anterior descending (LAD), left
circumﬂex (LCx), and right coronary arteries.nduced by 28 days, and several reports have investigated
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375he phasic, time-dependent cellular response after stent-
ng (29 –31).
AMPLING TIME POINTS (LATE STENT THROMBOSIS IN PRE-
LINICAL STUDIES). Pre-clinical studies of both sirolimus-
luting stents (SES) and paclitaxel-eluting stents (PES)
ave demonstrated their efficacy compared with that of
are-metal stents (6,8). However, enthusiasm for this tech-
ology has recently been dampened by concerns of late stent
hrombosis. It was not until the results of a study using
verlapping commercially available SES and PES stents in
he rabbit iliac artery model showed incomplete endothe-
ialization compared with matched bare-metal stent con-
rols that these differences were recognized (32). Human
ngioscopic and autopsy data have confirmed the signif-
cant differences in healing in the clinical setting (33,34).
wo studies using human autopsy samples suggested that
ncomplete endothelial coverage of stent struts played a
ery important role as the morphometric predictor of late
tent thrombosis (32,34). Recently, pre-clinical data from
ES, PES, and the Endeavor zotarolimus-eluting stent
Medtronic Vascular, Santa Rosa, California) have been
ompared (35). That study reported that incomplete
ndothelial coverage was seen in nonoverlapping and
verlapping sites of both SES and PES compared with
oth zotarolimus-eluting and bare-metal stents, though
he differences were more pronounced in overlapping
egments (Fig. 2).
The impairment of endothelialization after DES im-
lantation was to some extent attributed to the properties
f the durable polymer and/or drug that it eluted. To
ccelerate the process of endothelialization and thereby
educe the risk of thrombosis and restenosis, endothelial
rogenitor cell-captured stents were recently developed
ith immobilized antibodies targeted at endothelial pro-
enitor cell surface antigens. In in vivo porcine coronary
odels, a confluent monolayer of endothelial progenitor
ells over and between the struts of the stent was observed
t only 48 h after stent implantation and complete
ealing with mature neointima was observed at 28 days
fter stent implantation (36). The introduction of biode-
radable platforms and biocompatible polymers may
otentially address this issue. The pre-clinical study has
nvestigated the absorbable metallic stent composed of
agnesium alloy. Slottow et al. (37) observed the degra-
ation of a magnesium-based absorbable metallic stent
ver a 3-month period in the porcine coronary model
Fig. 3).
The U.S. Food and Drug Administration has typically
ecommended 6-month follow-up as the interval in which
o acquire pre-clinical stent data (9,22). Several time points
hould be used for the evaluation of DES performance, the
rst at 28 days to observe for neointimal hyperplasia, and ateast 1 later time point to examine long-term effects. The “ater time point (3 or 6 months) depends on when “healing”
nd drug release are both complete.
VERLAPPING STENT AND STENT FRACTURE. Stent overlap
ccurs often in clinical implants, and overlapping stent
mplantation presents the possibility of additive or synergis-
ic effects from a drug released from the overlapped sites.
re-clinical studies should be conducted in both single and
verlap models. Stent overlap is also good for evaluating
tent fracture, as it provides a hinge point for the distal
tent. Stent fracture represents an undesirable mechanical
ailure of the prosthesis that may introduce further vessel
all injury, potentiate an inflammatory or thrombotic re-
ponse, and corrupt drug delivery. Pre-clinical device studies
hould incorporate accepted methods to screen for acquired
trut fracture (22).
THER CONSIDERATIONS. The advance of DES technolo-
ies mandates special consideration. In vivo dissolution
hemistry, such as polymer and ceramics, should be docu-
ented by appropriately designed experiments with suffi-
ient temporal duration beyond material degradation using
istopathological methods or serial invasive/noninvasive
maging studies such as computed tomography, intravascu-
ar ultrasound, and optical coherence tomography. Another
onsideration relates to stents used for treatment of bifur-
ation and ostial lesions. Evaluation of these stent systems
oses additional challenges as they often have unique shapes
eflecting the peculiar anatomy they are intended to treat
nd/or may consist of several components. Their testing
ecessitates adequate anatomic models and increases the
omplexity of outcome analysis in the pre-clinical setting.
orcine heat-injury restenosis model. The porcine coronary
tent restenosis model is a well-accepted standard; however,
he fundamental drawback of this model is that the stent
tself is foreign material. As a result, this model may not be
uitable to evaluate the performance of bifurcation or
ioabsorbable stents due to a lack of a true stenotic lesion.
lso, results of coronary artery imaging such as computed
omography, magnetic resonance imaging, intravascular ul-
rasound, and optical coherence tomography may be ham-
ered as the stent can produce artifacts.
Using radiofrequency thermal balloon angioplasty, Staab
t al. (38) and our laboratory (21) have investigated a
orcine heat-injury restenosis model. In our study (21)
sing 22 swine with a total of 54 coronary arteries, coronary
rtery stenoses were consistently developed at 4 weeks after
eat injury (Fig. 4). In light of these results, this porcine
oronary restenosis model might be useful for the evaluation
f bifurcation stents and bioabsorbable stents, coronary
maging studies as previously listed, and as part of the
echnical training for complex percutaneous coronary inter-
entions such as bifurcation, diffuse lesion, and chronic total
cclusion (21).
nimal model of vulnerable plaque. The definition of a
vulnerable” plaque varies among the literature and is
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376onstantly being revised as clinicians and investigators gain
ore insight into the pathobiology of atherosclerosis and
he conditions that lead to acute coronary syndrome and
troke (39). It is now accepted that most clinical manifes-
ations of atherosclerosis such as acute myocardial infarction
MI), unstable angina, and sudden cardiac death result from
he development of an occlusive thrombus over an under-
ying plaque. There are various ways in which plaques can
ead to thrombus formation, the most common being plaque
upture (40). However, the mechanisms of plaque rupture
Figure 2. Comparison of Re-Endothelialization Among Drug-Eluting Stents
(A) X-rays of longitudinally cut rabbit iliac arteries at 21 days after placeme
Rosa, California), Cypher sirolimus-eluting stents (SES) (Cordis Corp., Bridge
Natick, Massachusetts). The extent of stent coverage by endothelial cells w
segments and signiﬁcantly greater coverage in the overlapped segment th
neointimal thickness at 28 days after placement of ZES, SES, PES, and Drive
focally uncovered stent struts, which were associated with inﬂammation co
from Nakazawa et al. (35).nd subsequent occlusive thrombus formation are still un- nlear. The need to identify and characterize vulnerable
therosclerotic lesions in humans has led to the develop-
ent of various animal models of plaque vulnerability.
MALL ANIMAL MODEL. Models have been developed pri-
arily in mice, rats, and rabbits in which plaque rupture was
ither induced or occurred spontaneously (41–43). Recent
odels of plaque vulnerability continue to make use of small
nimals, particularly mice; however, most do not result in
eatures of human end-stage atherosclerosis. Characteristics
f human vulnerable plaque such as plaque disruption,
overlapping Endeavor zotarolimus-eluting stents (ZES) (Medtronic, Santa
New Jersey), and Taxus paclitaxel-eluting stents (PES) (Boston Scientiﬁc,
atest with ZES, with almost complete coverage in the proximal and distal
s found with SES and PES. (B) Photomicrographs showing the amount of
-metal stents (Medtronic) in rabbit iliac arteries. With SES, there were
g of heterophils or eosinophils and giant cells. Adapted, with permission,nt of
water,
as gre
an wa
r bare
nsistineovascularization, intraplaque hemorrhage, and occlusive
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377hrombus formation occur rather infrequently in murine
odels. Also, lipoprotein metabolism in mice is largely
ifferent from that in humans, thus a murine model may not
e suitable for studies examining the effects of hypolipi-
emic therapies on atherosclerosis or MI.
ORCINE MODEL. Granada et al. (44,45) reported that
ercutaneous intramural injection of cholesteryl linoleate
esults in the development of complex, lipid-containing
nflammatory lesions in less than 4 weeks and that the
ntravascular ultrasound findings for the lesions in this
odel demonstrated similar features to those of complex
uman atherosclerotic plaques. However, this model is
ich in smooth muscle cells/proteoglycans and the lesions
Figure 3. IVUS, OCT Images, and Radiographs of Porcine Coronary Arteries
Intravascular ultrasound (IVUS) images: (A) just after implantation, (B) 4 weeks
phy (OCT) images: (D) just after implantation, (E) 4 weeks after implantation, (
Figure 4. Representative Coronary Angiogram of the Porcine Artery Treate
Time course of coronary artery treated with thermal balloon. A severe tandem
weeks after thermal balloon injury. Reprinted, with permission, from Suzuki et al. (21ack a necrotic core, calcification, and collagen (type I)
46). Therefore, this model might be more indicative of a
estenosis model.
ATANABE HERITABLE HYPERLIPIDEMIC RABBIT MODEL.
hiomi et al. (47) have developed the MI model, designated
he Watanabe heritable hyperlipidemic rabbit, in which sud-
en cardiac events occur spontaneously without any artificial
reatment. In their study, the cumulative incidence of fatal
udden cardiac events up to the age of 35 months was 97% and
epresentative findings of MI such as vulnerable plaques as
efined by Naghavi et al. (48) and thrombosis were observed in
he hearts of those rabbits. This Watanabe heritable hyper-
ipidemic MI rabbit could be a very useful model for studying
Absorbable Metallic Stent Implantation
implantation, (C) 3 months after implantation. Optical coherence tomogra-
onths after implantation. Adapted, with permission, from Slottow et al. (37).
Thermal Balloon
ary artery stenosis is observed in the left anterior descending artery at 4After
afterd With
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378he mechanism(s) of plaque rupture and thrombogenesis and
ould provide a novel means for developing new therapies or
maging technologies.
Currently, there is no standard animal model for vulner-
ble plaque. Animal models have been invaluable in eluci-
ating the pathobiology and complex processes of athero-
clerosis, but their use in studying vulnerable plaques and
nd-stage atherosclerosis remains limited. We should per-
aps focus our attention on unraveling the mechanisms of
cclusive thrombus formation as related to plaque disrup-
ions in humans through longitudinal imaging studies or
dentification of genes differentially expressed in human
esions (49).
xperimental chronic total occlusion (CTO) animal model.
ecent advances of DES technologies have shifted focus
ithin interventional cardiology to the treatment of CTO.
his interest has stimulated the development of specialized
evices (50,51). Despite its common occurrence, there is
ittle information about the pathophysiology of CTO. For
he past several years, researchers have developed CTO
nimal models to guide therapeutic investigations.
RADITIONAL CTO ANIMAL MODEL. The initial method of
roducing a total occlusion used external ligature or ameroid
onstriction (52). However, a fundamental drawback of this
ethod is the inability to facilitate the development of
evices to recanalize CTO. Subsequent techniques for
ndoluminal formation of CTO in coronary and peripheral
rteries have differed in their fundamental approach.
ECENT DEVELOPMENT OF CTO ANIMAL MODEL. Strauss
t al. (53) subsequently modified the thrombin injection
odel by infusing collagenase. Several characteristics of
uman CTO were evident in this model, including mature
brous tissue, multiple small intraluminal vascular channels,
ccasional extracellular lipid deposits, and disruption of the
nternal elastic lamina. Their reports (54) suggested that the
icrochannels may be a critical determinant of successful
TO guidewire crossing. Other CTO models have in-
luded stents with occluded outflow and even direct alcohol
njection to promote thrombosis (55). Developing an accu-
ate and reproducible humanlike coronary CTO model has
een very complex because: 1) simulating luminal and
edial pathology, including microcalcification, has been
ifficult; and 2) an inflammatory component must be
resent to mimic human CTO lesions (56,57). Both stan-
ard methods such as balloon angioplasty and stent implan-
ation in animal coronary arteries rarely result in CTO
evelopment. More aggressive measures have involved the
se of thermal injury and copper stent implantation as
escribed earlier (58). Polymers have also been used to
nvoke chronic coronary occlusions. Early polymeric im-
lants were abandoned as stent platforms because they
nduced severe inflammatory responses and vessel occlusion
59). Prosser et al. (60) reported placement of a microporous
oly L-lactic acid polymer into pig and dog coronary irteries. The polymer is absorbed by 28 days, resulting in a
icrochanneled occlusion histologically similar to a human
TO (60). Using similar methods, Suzuki et al. and our
roup (61,62) have developed severe calcified CTO in pig
oronary arteries (Fig. 5).
These animal models may contribute to a deeper under-
tanding of the biology of human CTO and enable new
evice and pharmacological investigations to improve recan-
lization success in these challenging lesions.
ercutaneous Interventions for
tructural Heart Disease
ecent advances of catheter-based intervention technologies
ave shifted focus to the treatment of structural heart
isease such as valvular heart disease (VHD) and patent
oramen ovale (PFO).
ercutaneous interventions for the treatment of VHD. Sur-
ical valve repair and replacement remain controversial as
ole treatments for patients with a low ejection fraction
ecause the morbidity and mortality rates of open-heart
urgery for these patients are still higher, and these recon-
tructive procedures have proven to be a challenge. Thus,
his fact is motivating scientists to design medical devices
hat can treat VHD in a minimally invasive manner.
echnical developments in valvular intervention culminated
n the first percutaneous valve replacement in the pulmonary
osition, followed by replacement in the aortic position
63,64). Based on the experience gained from the develop-
ent of surgical valve prostheses, the U.S. Food and Drug
dministration has established guidelines for the assess-
ent of valve implants as well as processes for in vitro and
n vivo pre-clinical testing of heart valve prostheses. In these
re-clinical studies, not only device development and dura-
ility testing, but also optimal imaging and deployment
rotocols should be established and comprehensive user
raining should be initiated in the latter stages of the
re-clinical evaluation (65).
ORTIC VALVE REPLACEMENT. Degenerative aortic steno-
is (AS), a common adult valvular abnormality (66), has
een the focus of percutaneous treatments. Two devices are
nder clinical investigation for percutaneous aortic valve
eplacement (67,68) (Fig. 6). A committee of experts
ummarized that this technique is feasible and provides
emodynamic/clinical improvement for up to 2 years in
atients with severe AS at high risk or with contraindica-
ions for surgery (69).
The ovine model is preferred for in vivo assessment of
ercutaneous aortic valve devices. Currently there is no ideal
nimal AS model. Even though the healthy ovine model has
rovided validation of catheter function, prosthesis anchor-
ng, device function after implantation, and unimpaired
c
t
o
s
h
a
M
c
P
i
m
p
s
m
v
p
(
p
t
o
T
a
S
h
p
c
a
t
t
r
f
d
u
a
r
b
e
M
i
f
(
h
a
p
i
c
M
4
3
f
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 5 , 2 0 0 9 Suzuki et al.
MA Y 2 0 0 9 : 3 7 3 – 8 3 Pre-Clinical Study in Interventional Cardiology
379oronary blood flow, this model has several limitations: 1)
he size of femoral arteries (typically5 mm); 2) angulation
f the aortic arch (the cause of kinking of the delivery
ystem); 3) the length of the aortic arch (shorter than that of
umans); and 4) the location of coronary ostia (closer to the
ortic valve than in humans).
ITRAL VALVE REPAIR. Mitral regurgitation (MR) can be
aused by a myriad of pathology and pathophysiology.
rimary leaflet disease, annular dilation due to dilated or
schemic cardiomyopathy, chordal abnormalities, papillary
uscle dysfunction, and left ventricular dilation displacing
apillary muscles can cause significant MR (70). Currently,
urgical techniques using an improved understanding of the
echanisms of mitral valve dysfunction coupled with ad-
ances in catheter-based technology have resulted in several
otential percutaneous approaches for mitral valve repair
71). Two approaches—edge-to-edge repair and annulo-
lasty—have been investigated in extensive pre-clinical
esting as shown in Table 1. The first phase I feasibility trial
f a percutaneous mitral device has been completed (72).
he pre-clinical results have confirmed the feasibility of this
pproach for creation of an edge-to-edge repair (72,73).
everal percutaneous technologies for mitral annuloplasty
ave been developed such as coronary sinus-based annulo-
lasty, direct intracavitary annuloplasty, and other novel
Figure 5. CTO in the Porcine Coronary Model
Angiogram at 4 weeks after implantation, demonstrating total occlusion of dis
total occlusion (CTO) lesion. Arrowheads show the collateral arteries. Elastic V
Adapted, with permission, from Suzuki et al. (62).inching devices (74–78). Shortening or reshaping the dnnulus by insertion of a device into the coronary sinus has
he potential to mimic surgical annuloplasty, and proof of
his concept has been demonstrated experimentally with the
ecent publication of an initial human feasibility study (79).
Similar to aortic valve devices, the ovine model is pre-
erred for in vivo assessment of percutaneous mitral valve
evices. Two types of diseased animal models were mainly
sed (74–77). One is the rapid-pacing heart failure model
nd the other is the ischemic MR model. The progressive
apid ventricular pacing for 5 to 8 weeks (180 to 240
eats/min) resulted in the reduction of left ventricular
jection fraction up to 24% to 28% and moderate-to-severe
R was developed (75,76,80). One drawback of this model
s that after recovery from rapid pacing, left ventricular
unction returns to normal levels in the healthy animals
81). Ischemic MR is induced by coronary arterial occlusion;
owever, variable anatomy of the coronary artery tree poses
challenge. Gorman et al. (82) has concluded that only
osterior infarction by occlusion of the left circumflex could
nduce acute or chronic ischemic MR. Also, the primary
oncern of this model is the mortality and consistency of
R development. Mortality related to MI is about 30% to
0% and reliability of MR development is about 20% to
0% (82). Thus, a “diseased” model might not be necessary
or device development or for durability testing of optimal
t anterior descending artery (A). Arrow indicates the proximal site of chronic
son (B) and Von Kossa (C) stained CTO segment of coronary arteries.tal lef
an Gieeployment protocols.
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380ercutaneous interventions for other structural heart dis-
ase. Stroke is the third leading cause of mortality in the
eveloped world. Atrial fibrillation and PFO can both
ontribute to cardioembolic stroke. Larger left arterial
ppendage (LAA) size and greater LAA dysfunction have
een found in patients with atrial fibrillation; therefore,
mputation of the LAA at the time of mitral valve surgery
as been recommended to reduce stroke risk. Recently,
ome groups have reported the efficacy and safety of percu-
aneous LAA occlusion in both pre-clinical and clinical
ettings (83,84). Patent foramen ovale is a congenital,
aplike opening between the atrial septa primum and
ecundum that persists after age 1 year.
Studies of cryptogenic stroke in young patients have
hown that the incidence of PFO is higher than in patients
ith established causes of stroke (85). Although the optimal
anagement of patients with symptomatic PFO remains
ontroversial, therapeutic options for secondary stroke pre-
ention include long-term medical treatment (platelet anti-
ggregating drugs or oral anticoagulation) and more invasive
trategies such as surgical repair and percutaneous PFO
losure. Optimal technological development will require
nderstanding the PFO at histologic, cellular, and tissue
Figure 6. The Cribier-Edwards Bioprosthesis
(A) Side and upper view of the stented valve. (B) The bioprosthesis in position
the crimped valve over the balloon. Adapted, with permission, from Eltchaninoevels. Animal models may also aid in this process (86). iole of the Animal Model as an Educational Tool
ith the advances of catheter-based intervention tech-
ologies, the indication of percutaneous catheter-based
ntervention has been extending and has shifted focus to
he complex procedures such as multivessel disease,
ifurcation lesions, unprotected left main trunk, and
TO lesions. Furthermore, new percutaneous catheter-
ased intervention technologies for VHDs such as AS
nd MR have been introduced in clinical settings (87).
lthough compared with the diseased human, animal
odels have several limitations, it should be very impor-
ant for interventionalists and surgeons to learn the
echniques, optimal imaging, and deployment protocols
f each interventional procedure. Thus, the role of animal
odels should be not only in device development and
urability testing, but also in physician training in opti-
al techniques involving new procedures.
onclusions
he field of percutaneous cardiovascular intervention tech-
ology is evolving rapidly. The basic concepts will be
id-part of the balloon before crimping. (C) The crimping phase. (D) A view of
l. (87).at mmportant to understand as all further advances will be
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381enerated by the early beginnings including pre-clinical
tudies. The experience gained with pre-clinical models
ermits better understanding of the important relationships
etween the models and the clinical results. In addition, the
ole of animal models should be not only in device devel-
pment and durability testing, but also in training for
nterventionalists and surgeons in optimal techniques in-
olving new procedures. Over the next decade, clinical trials
ill clarify the roles of these new approaches in relation to
ach other and to current surgical and medical therapies.
here is a fundamental knowledge, skill set, and clinical
isdom of general physicians, imaging specialists, interven-
ionalists, and surgeons that must be shared, coordinated,
nd synchronized to ensure successful outcomes and future
evelopment of the new techniques. A new era is coming
et again for the discipline of cardiovascular diseases that
ill be driven by the results of a collaborative relationship
etween the cardiologist, cardiac surgeon, and the medical
evice industry, benefiting the patient with symptomatic
ardiovascular disease.
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Phase I clinical trial
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element
Pre-clinical
Mitralign Transventricular suture-based
system using coronary sinus
as anatomic guide
Phase I clinical trial
Accucinch (Guided
Delivery Systems)
Transventricular annular cinching Pre-clinical
Cordis (J&J) Transventricular annular cinching Pre-clinical
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Pre-clinical
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